Trientine tetrahydrochloride (Cuprior®) the treatment of Wilson’s disease
The National Health Care Institute has completed its assessment whether trientine tetrahydrochloride (Cuprior®) is interchangeable with a product that has been included in the Medication Reimbursement System (GVS). The National Health Care Institute's advice is to include trientine tetrahydrochloride (Cuprior®) in Appendix 1B and Appendix 2 of the Health Insurance Regulation and to impose additional conditions.
Registered indication
Cuprior® is indicated for the treatment of Wilson’s disease (WD) in adults and and children older than 5 years who are intolerant to therapy with D-penicillamine. Cuprior® is available as a film-coated tablet containing trientine tetrahydrochloride (trientine 4HCL), equivalent to 150 mg trientine.
Assessment
The National Health Care Institute has come to the final conclusion that trientine tetrahydrochloride (Cuprior®) has an equal therapeutic value for the treatment of patients with Wilson's disease who are intolerant to therapy with D-penicillamine compared to trientine dihydrochloride (Cufence®). Because Cufence® is not included in the GVS, Cuprior® is eligible for placement on List 1B.
The National Health Care Institute's advice
Based on the considerations mentioned in the report, the National Health Care Institute advises the Minister for Medical Care to include trientine tetrahydrochloride (Cuprior®) in Appendix 1B and Appendix 2 (with additional conditions).
This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.